Maxim Group Analysts Give ContraVir Pharmaceuticals (CTRV) a $4.00 Price Target

ContraVir Pharmaceuticals (NASDAQ:CTRV) has been given a $4.00 price target by investment analysts at Maxim Group in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.

Separately, ValuEngine raised shares of ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

ContraVir Pharmaceuticals (NASDAQ CTRV) traded up $0.01 during trading on Monday, hitting $0.25. 394,400 shares of the stock were exchanged, compared to its average volume of 823,082. ContraVir Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $1.96. The stock has a market capitalization of $19.71, a price-to-earnings ratio of -0.51 and a beta of 1.92.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. lifted its holdings in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,414,475 shares of the biopharmaceutical company’s stock after purchasing an additional 366,192 shares during the quarter. Vanguard Group Inc. owned about 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 6.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply